NasdaqGS - Nasdaq Real Time Price USD

Exelixis, Inc. (EXEL)

21.97 +0.27 (+1.27%)
As of 12:12 PM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
1,846,646.00
1,830,208.00
1,611,062.00
1,434,970.00
987,538.00
--
Cost of Revenue
79,488.00
72,547.00
57,909.00
52,873.00
36,272.00
--
Gross Profit
1,767,158.00
1,757,661.00
1,553,153.00
1,382,097.00
951,266.00
--
Operating Expense
1,562,806.00
1,586,776.00
1,351,669.00
1,095,431.00
841,206.00
--
Operating Income
204,352.00
170,885.00
201,484.00
286,666.00
110,060.00
--
Net Non Operating Interest Income Expense
86,935.00
86,543.00
33,065.00
7,672.00
19,865.00
--
Other Income Expense
-32,777.00
93.00
-197.00
-184.00
912.00
--
Pretax Income
258,510.00
257,521.00
234,352.00
294,154.00
130,837.00
--
Tax Provision
53,456.00
49,756.00
52,070.00
63,091.00
19,056.00
--
Net Income Common Stockholders
205,054.00
207,765.00
182,282.00
231,063.00
111,781.00
--
Diluted NI Available to Com Stockholders
205,054.00
207,765.00
182,282.00
231,063.00
111,781.00
--
Basic EPS
0.65
0.65
0.57
0.73
0.36
--
Diluted EPS
0.65
0.65
0.56
0.72
0.35
--
Basic Average Shares
312,235.25
318,151.00
321,526.00
314,884.00
308,271.00
--
Diluted Average Shares
316,276.75
321,464.00
324,556.00
322,359.00
318,001.00
--
Total Operating Income as Reported
171,517.00
170,885.00
201,484.00
286,666.00
110,060.00
--
Total Expenses
1,642,294.00
1,659,323.00
1,409,578.00
1,148,304.00
877,478.00
--
Net Income from Continuing & Discontinued Operation
205,054.00
207,765.00
182,282.00
231,063.00
111,781.00
--
Normalized Income
231,099.21
207,765.00
182,282.00
231,063.00
111,781.00
--
Interest Income
86,935.00
86,543.00
33,065.00
7,672.00
19,865.00
--
Net Interest Income
86,935.00
86,543.00
33,065.00
7,672.00
19,865.00
--
EBIT
204,352.00
170,885.00
201,484.00
286,666.00
110,060.00
--
EBITDA
229,592.00
196,602.00
222,359.00
300,296.00
119,201.00
--
Reconciled Cost of Revenue
79,488.00
72,547.00
57,909.00
52,873.00
36,272.00
--
Reconciled Depreciation
25,240.00
25,717.00
20,875.00
13,630.00
9,141.00
--
Net Income from Continuing Operation Net Minority Interest
205,054.00
207,765.00
182,282.00
231,063.00
111,781.00
--
Total Unusual Items Excluding Goodwill
-32,835.00
--
--
--
--
--
Total Unusual Items
-32,835.00
--
--
--
--
--
Normalized EBITDA
262,427.00
196,602.00
222,359.00
300,296.00
119,201.00
--
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
--
Tax Effect of Unusual Items
-6,789.79
--
--
--
--
--
12/31/2019 - 4/17/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

INCY Incyte Corporation
58.79
+1.72%
 
BMRN BioMarin Pharmaceutical Inc.
76.64
+2.08%
 
AXSM Axsome Therapeutics, Inc.
74.53
+1.50%
 
ACAD ACADIA Pharmaceuticals Inc.
15.18
+0.53%
 
MDGL Madrigal Pharmaceuticals, Inc.
242.00
+2.47%
 
AGEN Agenus Inc.
16.59
+5.74%
 
IONS Ionis Pharmaceuticals, Inc.
39.01
+3.82%
 
BBIO BridgeBio Pharma, Inc.
28.62
+2.18%
 
HALO Halozyme Therapeutics, Inc.
44.84
+1.24%
 
IOVA Iovance Biotherapeutics, Inc.
8.60
-3.15%